光生物调节疗法治疗巴西女性乳腺癌相关急性放射性皮炎:随机对照试验研究方案
本研究为三盲随机对照试验,计划纳入96例接受放疗的乳腺癌患者,随机分为对照组(安慰剂+机构标准方案,n=48)和干预组(光生物调节疗法+标准治疗,n=48)。干预采用激光治疗仪(100mW,连续模式,红光波长660±20 nm,能量密度10.16 J/cm2,每点能量1 J),每周三次,放疗前进行。主要结局为采用RTOG急性放射损伤评分标准每周评估皮肤反应,并分析热成像及生活质量问卷(EORTC QLQ-30和EORTC QLQ-BR23)结果。
要点
- 三盲随机对照试验,计划纳入96例乳腺癌放疗患者,干预组和对照组各48例。
- 光生物调节疗法参数:100mW,连续发射,红光660±20 nm,能量密度10.16 J/cm2,每点1 J,每周三次,放疗前进行。
- 主要评估指标包括RTOG急性放射损伤评分、热成像及EORTC生活质量问卷。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Radiodermatitis is one of the most common radiotherapy-related side effects, which can influence patients' quality of life and affect therapeutic efficacy. Photobiomodulation therapy (PBMT) appears as a low-cost technology, with significant results in the tissue repair process. METHODS: It is a triple blind randomized controlled trial. A total of 96 patients undergoing radiotherapy for breast cancer are estimated for the sample, which will be randomly assigned to a control group to receive a placebo and the institution's standard protocol (n = 48) or to an intervention group to receive PBMT, in addition to standard therapy (n = 48). The intervention consists of applying Laser Therapy EC (DMC™, São Carlos-SP, Brazil), with power of 100mW, continuous emission mode, red wavelength (660 ± 20 nm), fluence of 10.16 J/cm2, and energy of 1 J per point, three times a week since day one, right before the radiotherapy session. Blinding will be applied to patients, evaluators, and the statistician. Skin reactions will be assessed weekly using the Acute Radiation Morbidity Scoring Criteria developed by the Radiation Therapy Oncology Group and thermal images of the irradiated area that will be captured. In addition, the impact of radiodermatitis on the quality of life will be assessed through the application of the Cancer Quality of Life Questionnaire (EORTC QLQ-30) and the Breast Cancer Quality of Life Questionnaire (EORTC QLQ -BR23) at the beginning and in the end of treatment. Data will be processed and analyzed by the statistical package R using descriptive and inferential statistics. DISCUSSION: Photobiomodulation stands out for being a non-invasive and low-cost therapy that has not been associated with adverse events. It used to stimulate wound healing by promoting tissue repair, by reducing inflammation, by stimulating collagen synthesis, and relieving pain. Cientific literature have been highlighted PBMT as an effective tool in preventing or reducing the severity of radiodermatitis and its associated symptoms, which expected to be demonstrated with this ongoing study. TRIAL REGISTRATION: Brazilian Clinical Trials Registry (ReBEC - Registro Brasileiro de Ensaios Clínicos) - Id. RBR-7gkw3d4; Universal Trial Number (UTN) - Id. U1111-1279-1686; Plataforma Brasil/Research Ethics Committee - Id. 5.788.390, registered on 24 August 2022. https://ensaiosclinicos.gov.br/rg/RBR-7gkw3d4 .
引用
- Silva SRRC, da Costa Veloso L, Silva RC, et al. Photobiomodulation therapy in breast cancer-related acute radiodermatitis cases in Brazilian women: study protocol for a randomized controlled trial. Trials. 2026. PMID: 41491205. doi:10.1186/s13063-025-09294-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。